Etoposide as Salvage Therapy for Cytokine Storm Due to Coronavirus Disease 2019

Coronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality because of a lack of effective therapies. Therapeutic strategies under investigation target the overactive cytokine response with anti-cytokine or immunomodulators therapies. We present a unique case of severe cy...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Maulin, Dominguez, Eduardo, Sacher, Daniel, Desai, Parag, Chandar, Ashwin, Bromberg, Michael, Caricchio, Roberto, Criner, Gerard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Chest Physicians. Published by Elsevier Inc. 2021
Materias:
Novel Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486855/
https://www.ncbi.nlm.nih.gov/pubmed/32931823
http://dx.doi.org/10.1016/j.chest.2020.09.077
Descripción
Sumario:Coronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality because of a lack of effective therapies. Therapeutic strategies under investigation target the overactive cytokine response with anti-cytokine or immunomodulators therapies. We present a unique case of severe cytokine storm resistant to multiple anti-cytokine therapies, but eventually responsive to etoposide. Thus, etoposide may have a role as salvage therapy in treatment of cytokine storm in COVID-19. To our knowledge, this is the first reported case of use of etoposide in COVID-19.

Ejemplares similares